8-K: TerrAscend Completes Apothecarium Acquisition, Announces CFO Transition

TerrAscend Corp. finalized its acquisition of the remaining 50.1% of Apothecarium Entities and announced the resignation of CFO Keith Stauffer, effective July 18, 2025, with Alisa Campbell appointed as interim lead.

Summary

• TerrAscend Corp. completed the acquisition of the remaining 50.1% equity interests in RHMT, LLC, Deep Thought, LLC, and Howard Street Partners, LLC (collectively, the Apothecarium Entities).
• The Company issued an aggregate of 5,457,898 common shares to the seller parties for the acquisition.
• The shares were issued at a price of $0.38 per share, representing the twenty-day volume-weighted average price on the OTCQX for the period ending May 20, 2025, for a total aggregate value of $2,074,002.38.
• Keith Stauffer notified the Company of his decision to resign as Chief Financial Officer (CFO), effective July 18, 2025.
• Alisa Campbell, currently Senior Vice President, Corporate Finance & Accounting, will assume leadership of the Company's accounting and finance function on an interim basis upon Mr. Stauffer's departure.
• A comprehensive search for a permanent CFO is currently underway.

Sentiment

Score: 6

Explanation: The completion of the Apothecarium acquisition is a positive step for consolidation. The CFO departure is a negative, but the planned transition and experienced interim replacement mitigate the immediate concern. The overall tone is managed, and no significant negative financial news is presented.

Positives

• Completion of the Apothecarium Entities acquisition, consolidating ownership and streamlining operations.
• Planned and orderly CFO transition with Keith Stauffer remaining in his role until July 18, 2025, to ensure a smooth handover.
• Appointment of an experienced internal candidate, Alisa Campbell, as interim CFO, who has over 20 years of financial leadership experience and deep knowledge of TerrAscend's financial infrastructure and operations.
• Management expresses confidence in the interim CFO's abilities to ensure continuity.

Negatives

• Departure of Keith Stauffer, an experienced CFO who played a significant role in strengthening the company's financial foundation and navigating the cannabis industry for five years.
• The company will operate with an interim CFO while a search for a permanent replacement is conducted, which could introduce a period of uncertainty.

Risks

• Cannabis remains a Schedule I drug under the U.S. Controlled Substances Act, making it illegal under federal law to cultivate, distribute, or possess cannabis in the United States.
• Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable U.S. federal money laundering legislation.
• Strict compliance with state laws regarding cannabis will neither absolve TerrAscend of liability under U.S. federal law nor provide a defense to any federal proceeding.
• The enforcement of federal laws in the United States is a significant risk that could adversely affect TerrAscend's operations and financial performance.

Future Outlook

The company expects to continue its ongoing cost reduction efforts, achieve productivity gains, and make overall operational improvements. It also anticipates market opportunities, further expansion efforts, and execution of its M&A strategy, including the expected closing of signed acquisitions and anticipated profitability of acquired dispensaries. Additionally, the company foresees potential benefits from facility expansions and expects the timing for the first harvest in Hagerstown, Maryland.

Management Comments

• "On behalf of the Board and the entire TerrAscend team, I want to thank Keith for his leadership and contributions over the past five years. He played a pivotal role in strengthening our financial foundation, driving strategic growth, and navigating the complexities of the cannabis industry. He assembled a highly experienced team and implemented industry-leading financial and operating controls to support our future growth. We wish him continued success in his next chapter." Jason Wild, Executive Chairman of TerrAscend.
• "I am deeply grateful to the leadership team, our employees, and the Board for their trust and support over the years. This decision was not easy, but I was presented with an opportunity I could not turn down. I am committed to supporting a smooth transition and look forward to following the Company's success as both an investor and a friend." Keith Stauffer, Chief Financial Officer.
• "I have full confidence in Alisa's leadership and abilities. She has been instrumental in shaping our financial strategy and has partnered closely with Keith and I to build a strong financial foundation at TerrAscend. Her deep knowledge of our operations, supported by a strong bench will ensure continuity as we move forward." Ziad Ghanem, President and Chief Executive Officer of TerrAscend.

Industry Context

The cannabis industry in the U.S. continues to operate under a complex regulatory environment where cannabis is federally illegal despite state-level legalization. Companies like TerrAscend, with vertically integrated operations across multiple states (Pennsylvania, New Jersey, Maryland, Michigan, California), navigate these challenges while pursuing growth through acquisitions and operational efficiencies. The departure of a CFO to pursue opportunities outside the cannabis industry highlights the unique regulatory and operational pressures within the sector.

Comparison to Industry Standards

• The document does not provide specific financial performance metrics (e.g., revenue growth, profit margins) that would allow for a direct comparison to industry standards or specific comparable companies.
• The acquisition of the remaining 50.1% of Apothecarium Entities is a strategic move to consolidate ownership, a common practice in consolidating industries like cannabis, but no specific valuation metrics are provided for comparison.
• The CFO transition is a common corporate event, and the appointment of an internal candidate (Alisa Campbell) as interim CFO with extensive company knowledge is a standard practice to ensure continuity during a search for a permanent replacement.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Experience dilution from the issuance of 5,457,898 common shares for the Apothecarium acquisition; potential impact on share price due to CFO transition.
• Employees: Will see a change in senior leadership within the finance function; continuity is provided by the internal interim appointment.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Conduct a comprehensive search for a permanent Chief Financial Officer.
• Keith Stauffer will remain in his role until July 18, 2025, to ensure a smooth transition of responsibilities.
• Alisa Campbell will assume interim leadership of the accounting and finance function upon Mr. Stauffer's departure.
• Continue ongoing cost reduction efforts, productivity gains, and overall operational improvements.
• Pursue further market opportunities, expansion efforts, and M&A strategy execution.
• Work towards the expected closing of signed acquisitions and anticipated profitability of acquired dispensaries.
• Proceed with facility expansions and prepare for the expected timing for the first harvest in Hagerstown, Maryland.

Key Dates

Recommendation

Keywords

Cannabis, SEC Filing, 8-K, TerrAscend, Apothecarium, Acquisition, CFO, Chief Financial Officer, Resignation, Corporate Governance, Equity Issuance, OTCQX, TSNDF, Financial Reporting, Risk Management, US Cannabis Law